AI CuratorAI-generated

Research summary · 10 d ago

AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

Animal Study with EBV Peptide Microarray

In a study involving 329 specimens, researchers validated a peptide microarray targeting nine EBV proteins. They found broad EBV humoral reactivity in individuals with infectious mononucleosis (IM), multiple sclerosis (MS), and non-MS donors. Notably, they replicated patterns of EBNA-1 C-terminal reactivity associated with MS but determined that overall EBV reactivity does not provide a clear signal to distinguish MS from non-MS samples.

Tags: #EBV
Most relevant to: —
Source: Read original source (PMID 42756034)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This work supports understanding the relationship between EBV and MS, suggesting that EBV exposure is widespread and not solely MS-specific. It highlights the complexity of using EBV reactivity as a diagnostic tool for MS.

What this does not prove

The study did not provide a straightforward MS-discriminating profile. Furthermore, only a limited number of EBV epitopes were relevant to distinguishing MS from other cohorts, indicating that broad EBV exposure is not unique to MS.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 329 · Number of specimens collected.
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-03
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: EBV

Original sources

Primary evidenceAnalytical validation of a multiplexed peptide microarray for multi-antigen Epstein-Barr virus serological profiling across diverse clinical specimens. ↗DOI: 10.3389/fimmu.2026.1919983

Supporting passages (8)

sample size329

sample size basisMETHODS: Here we report the analytical validation of a 108-peptide microarray spanning nine EBV proteins, applied to 329 specimens collected as serum, EDTA plasma, and Streck cell-free DNA (cfDNA) blood collection tubes.

research categoriesEBV

publication date2026-09-03

interventionMETHODS: Here we report the analytical validation of a 108-peptide microarray spanning nine EBV proteins, applied to 329 specimens collected as serum, EDTA plasma, and Streck cell-free DNA (cfDNA) blood collection tubes.

findingsWhen applied to IM, MS, and non-MS donors, the peptide array consistently detected broad EBV humoral reactivity.

limitationsIn this proof-of-concept disease-cohort analysis, the array recapitulated biologically relevant EBNA-1 C-terminal reactivity patterns previously associated with MS-related molecular mimicry, but array-wide EBV reactivity did not yield a simple MS-discriminating signature.

limitationsAlthough EBV reactivity has been reported to distinguish MS from non-MS cohorts, only a very small set of EBV epitopes was cohort-associated in our data, indicating that platform-level seropositivity reflects EBV exposure rather than an obvious MS-specific signal.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.